Fig. 1

Design of the two studies presented. Number and type of participants, along with the timing of sample collection and the type of analysis performed are included. 1In patients with CD and SGRS. 2In patients with CD. 4 h, 4 hours; anti-TG2, anti-transglutaminase type 2; CD, celiac disease; GC, gluten challenge; GIP, gluten immunogenic peptides; IELs, intraepithelial lymphocytes; SGRS, suspected gluten-related functional bowel disease symptoms